Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPQE2S)

• Drug Name: LVGN6051 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMPQE2S

Molecule-Related Drug Atlas

Drug(s) Targeting Co-stimulatory molecule 4-1BB (CD137)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Urelumab	DM6RTVG	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[3]
Anti-CD137	DMHVZ27	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
MG7-CART	DME6PB0	Acute myeloid leukaemia	2A60	Phase 1/2	[5]
NM21-1480	DMDNJP5	Advanced solid tumour	2A00-2F9Z	Phase 1/2	[6]
CD137 CAR-T Cell	DMHMC19	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[7]
ADG106	DM87H0S	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[8]
CD28 and CD137 CAR-T Cells	DMFGQXB	Acute lymphoblastic leukaemia	2A85	Phase 1	[9]
MCLA-145	DM8CGUV	Lymphoma	2A80-2A86	Phase 1	[10]
GEN1046	DMEWRNZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
INBRX-105	DM2FH10	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Co-stimulatory molecule 4-1BB (CD137)	TTPW9LJ	TNR9_HUMAN	Activator	[2]

References

• [1] ClinicalTrials.gov (NCT04130542) Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (MK-3475-A31/KEYNOTE-A31) in Advanced or Metastatic Malignancy. U.S. National Institutes of Health.
• [2] Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcR affinity. Nat Commun. 2019 May 20;10(1):2141.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878).
• [5] ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
• [6] Clinical pipeline report, company report or official report of Numab Therapeutics.
• [7] ClinicalTrials.gov (NCT02965092) CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
• [8] Clinical pipeline report, company report or official report of Adagene.
• [9] ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
• [10] Clinical pipeline report, company report or official report of Merus.
• [11] Clinical pipeline report, company report or official report of Genmab.
• [12] Clinical pipeline report, company report or official report of Inhibrx.